Voisin Consulting Life Sciences publication icon

Market Access for ATMPs Begins at the Bench

Post thumbnail Market Access for ATMPs Begins at the Bench

Despite their significant therapeutic potential, ATMPs face specific market access challenges compared to other therapeutic categories. These include high manufacturing costs, incremental benefit claims that extend over an extended time frame, restriction to centres of excellence and disruption of existing service delivery processes, often requiring significant reallocation of healthcare resources. Development, manufacturing and commercialisation are highly co-dependent processes and do not exist in the sequential, standalone systems in which small molecules and biologics function. In order for commercialisation to be successful, a constant feedback loop should be in place early on in development that drives quality, efficiency, scalability and patient-centred treatment management.

Voisin Consulting Life Sciences download icon

Download the full publication now

Fill in the form to download the content

    Yes, I would like to receive communications regarding VCLS services and events

    publication by

    Gopalan Narayanan
    Gopalan Narayanan, M.D.
    Vice President, Disruptive Biologics
    Dr. Narayanan provides leadership within the area of complex and disruptive biologics such as Cell and Gene therapies, called Advanced…
    View profile